Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 234 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism and Excretion Clear all

Conditions: Healthy Volunteer
Interventions: CC-220, [14C]; Drug · Radiation
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dyslipidemia
Interventions: K-312 100 mg, K-312 100 ug C14 IV; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 25 Years to 45 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Osteoporosis
Interventions: rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more

Conditions: Healthy Subjects (HS)
Interventions: zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: 14C PER977; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 15 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: CC-90009, [14C]; Drug · Radiation
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cerebral Hyponatremia, SIADH, Cerebral Salt-wasting Syndrome, Reset Hypothalamic Osmostat
Interventions: Tolvaptan in euvolemic hyponatremia; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Healthy
Interventions: Talampanel (non-radiolabeled), [14C] Talampanel; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-LX4211; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions: TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Absorption, Metabolism and Excretion in Healthy Volunteers
Interventions: [14C]-PBI-200; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: BMS-986166, Bisacodyl; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Samidorphan IV, [14c]-Samidorphan sublingual, [14c]-Samidorphan oral; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Radiolabeled SPD557; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: TD-4208; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Elevated HMB Excretion
Interventions: Statin user; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Neuropathic Pain
Interventions: BIIB074; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Fadraciclib; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Emraclidine; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metabolism and Elimination
Interventions: E2609; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-CC-92480; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Thalassemia, Iron Overload, Hemochromatosis
Interventions: Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram; Drug · Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: [14C]-DNL343; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Radiolabeled Study of CC-220 in Healthy Male Subjects

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

Fractional Urate Excretion in Nonedematous Hyponatremia

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers

Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Cholesterol and Statin in Healthy Adults

Absorption, Metabolism, and Excretion Study of BIIB074

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

Oral Nifedipine to Treat Iron Overload

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants